Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Bender Robert & Associates

Bender Robert & Associates cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 20.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,619 shares of the life sciences company’s stock after selling 8,960 shares during the period. Illumina accounts for 1.1% of Bender Robert & Associates’ portfolio, making the stock its 19th largest position. Bender Robert & Associates’ holdings in Illumina were worth $4,760,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. WCM Investment Management LLC increased its stake in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after purchasing an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Illumina by 0.8% during the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock valued at $454,617,000 after purchasing an additional 27,618 shares during the last quarter. Geode Capital Management LLC increased its stake in Illumina by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after purchasing an additional 48,018 shares during the last quarter. Primecap Management Co. CA increased its stake in Illumina by 3.6% during the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after purchasing an additional 87,599 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

ILMN stock opened at $84.52 on Wednesday. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66. The firm has a market capitalization of $13.39 billion, a PE ratio of -11.01, a P/E/G ratio of 1.60 and a beta of 1.17. The firm has a 50-day moving average of $116.45 and a two-hundred day moving average of $130.84.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of several recent research reports. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $130.00 to $100.00 in a research note on Monday, February 10th. Stephens restated an “overweight” rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday. Canaccord Genuity Group lowered their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday. Morgan Stanley lowered their price target on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 11th. Finally, TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and lowered their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $146.85.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.